Bleomycin
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Bleomycin: From Hodgkin Lymphoma and Other Lymphomas to Reticulum Cell Sarcoma (Lymphoma)
One-Sentence Summary
Bleomycin is a cytotoxic antibiotic originally used to treat Hodgkin and non-Hodgkin lymphomas and head and neck cancer. The TxGNN model's top-ranked prediction is cauda equina neoplasm, but this has no supporting evidence. The best-supported candidate is reticulum cell sarcoma (an archaic term for non-Hodgkin lymphoma), backed by 11 clinical trials and 20 publications. This is largely a match to an existing indication rather than true repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hodgkin lymphoma, non-Hodgkin lymphoma, head and neck cancer (from the knowledge graph; no approved indication text is available in the New Zealand licence records) |
| Predicted New Indication | Top-ranked by score: cauda equina neoplasm (99.30%, L5, Hold). Best-supported: reticulum cell sarcoma (99.14%) |
| TxGNN Prediction Score | 99.30% (cauda equina neoplasm); 99.14% (reticulum cell sarcoma) |
| Evidence Level | L1 (reticulum cell sarcoma) |
| New Zealand Market Status | Cancelled only |
| Number of Authorizations | 2 (0 valid, 2 cancelled) |
| Recommended Decision | Proceed with Guardrails (reticulum cell sarcoma); Hold for the top-ranked cauda equina neoplasm |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Bleomycin is a well-known cytotoxic agent that causes DNA strand breaks. Its efficacy in Hodgkin and non-Hodgkin lymphoma is established, and it is a component of regimens such as ABVD, ProMACE-CytaBOM, VACOP-B and m-BACOD.
Reticulum cell sarcoma is an outdated term for diffuse large B-cell or non-Hodgkin lymphoma, which already falls within bleomycin's established lymphoma indications. Early clinical reports from the 1970s describe bleomycin activity in reticulum cell sarcoma, and later trials tested bleomycin-containing combination regimens. Caveat: these trials test combinations, so bleomycin's individual contribution is not isolated, and bleomycin is no longer standard in many modern DLBCL regimens (e.g. R-CHOP).
The other predictions are weaker:
- Cauda equina neoplasm (rank 1): no trials, and the single retrieved paper concerns radiotherapy for CNS germinoma. Poor CNS penetration is a major barrier. (L5, Hold)
- Adult astrocytic tumour (rank 2): only early-phase or dated studies in glioma, including a phase I intratumoral infusion trial. A randomized trial showed no survival benefit from adding bleomycin. (L3, Research Question)
- Primary pulmonary lymphoma (rank 4): plausible, but no study evaluates bleomycin in this setting, and lung toxicity is especially relevant. (L4, Research Question)
- Pulmonary blastoma (rank 5): two case reports only. (L4, Hold)
- Well-differentiated fetal adenocarcinoma of the lung (rank 6): no evidence. (L5, Hold)
Clinical Trial Evidence
Shown for reticulum cell sarcoma (the other predicted indications have no registered trials).
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00005867 | Phase 3 | Completed | 310 | CHOP vs PMitCEBO in good-risk aggressive non-Hodgkin lymphoma |
| NCT00002835 | Phase 3 | Completed | 116 | Early intensification vs alternating triple therapy in poor-prognosis lymphoma |
| NCT00002565 | Phase 3 | Completed | 61 | Alternating triple therapy vs CHOP in intermediate-grade/immunoblastic lymphoma; bleomycin contribution not isolated |
| NCT00003815 | Phase 3 | Unknown | N/A | High-dose chemoradiotherapy with autologous transplant in high-grade NHL; bleomycin role unclear |
| NCT00003110 | Phase 2 | Completed | 5 | 72-hour continuous-infusion bleomycin as salvage in AIDS-related and immunocompetent NHL; bleomycin-specific but very small |
| NCT00002571 | Phase 2 | Completed | 52 | ProMACE-CytaBOM plus antiviral therapy and G-CSF in AIDS-related lymphoma |
| NCT00002524 | Phase 2 | Completed | 46 | Combination chemotherapy pilot in AIDS-related lymphoma |
| NCT00002657 | Phase 2 | Completed | 20 | ProMACE-CytaBOM with immunomodulation in post-cardiac-transplant lymphoproliferation |
| NCT00032149 | Phase 1/2 | Unknown | 30 | PMitCEBO plus G-CSF in good-prognosis HIV-related lymphoma |
| NCT00031902 | Phase 1 | Unknown | N/A | Rituximab plus PVB chemotherapy in HIV-related NHL |
Literature Evidence
Shown for the indications with the most relevant publications; reticulum cell sarcoma and adult astrocytic tumour are the main ones.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 4109401 | 1972 | Clinical study | Br Med J | Single-agent bleomycin in 54 Hodgkin, 17 lymphosarcoma, 22 reticulum cell sarcoma and 7 mycosis fungoides patients after prior therapy; 29% of Hodgkin patients remitted |
| 4107632 | 1971 | Clinical study | Arch Dermatol | Bleomycin in mycosis fungoides and reticulum cell lymphoma |
| 14962711 | 2004 | Randomised trials (pooled) | Eur J Cancer | Long-term efficacy of the bleomycin-containing CHVmP/BV regimen in 936 aggressive NHL patients across three EORTC trials |
| 24014242 | 2013 | Pooled analysis | Blood | Treatment factors in 1,546 HIV-associated NHL patients from 19 prospective trials |
| 27888880 | 2016 | Review | Hematol Oncol Clin North Am | Optimizing outcomes in primary mediastinal B-cell lymphoma |
| 15202521 | 2003 | Review | Leuk Lymphoma | MACOP-B (includes bleomycin) followed by radiotherapy may be a better induction strategy in PMBL |
| 6187214 | 1983 | Case report | Am J Med | Fatal bleomycin-induced hyperpyrexia in a lymphoma patient |
| 6164465 | 1981 | Randomised trial | Cancer | Grade III-IV astrocytoma: radiotherapy was valuable, but bleomycin did not improve survival |
| 12416544 | 2002 | Phase I trial | J Neurooncol | Continuous intratumoral bleomycin infusion in recurrent glioblastoma; feasibility study |
| 31668826 | 2020 | Cohort | J Geriatr Oncol | Age and bleomycin pulmonary toxicity risk in Hodgkin lymphoma |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2204215 | Baxter | Inj 1,000 iu for ECP | Not available (status: cancelled) |
| 2343207 | DBL Bleomycin Sulfate | Inj 15,000 iu, vial | Not available (status: cancelled) |
Both licences are cancelled, so there is currently no valid marketed bleomycin product in New Zealand.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (antitumour antibiotic; causes DNA strand scission) |
| Myelosuppression Risk | Low relative to other cytotoxics (the 1972 report notes marrow-sparing properties); please refer to the package insert |
| Emetogenicity Classification | Low |
| Monitoring Items | Pulmonary function and chest imaging (pulmonary toxicity is the key concern), plus CBC, liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Pulmonary toxicity: The literature repeatedly reports bleomycin-induced interstitial pneumonitis and pulmonary toxicity, with risk increasing with age (PMIDs 4118423, 31668826, 27742539). This is especially relevant for lung-based indications.
- Hyperpyrexia: A fatal acute hyperpyrexic reaction has been reported, and a test dose before therapy has been recommended (PMID 6187214).
- Drug interactions: 205 interactions were identified. The ones listed in the data are mostly of unknown severity (e.g. pantoprazole, omeprazole, morphine, prednisone, vancomycin, ondansetron, clarithromycin); levofloxacin is classified as minor.
The package insert warnings and contraindications could not be retrieved. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails (reticulum cell sarcoma / non-Hodgkin lymphoma); Hold for cauda equina neoplasm and other low-evidence predictions
Rationale:
- Reticulum cell sarcoma has multiple completed Phase 3 trials and historical single-agent data, but it is effectively an existing lymphoma indication, and the trials test combination regimens, so bleomycin's own contribution is unclear. The top-scoring cauda equina neoplasm prediction has no supporting evidence and faces CNS penetration barriers.
- Both New Zealand licences are cancelled, so a supply route would also need to be established.
To proceed, the following is needed:
- Package insert warnings and contraindications from Medsafe (currently a blocking gap for safety screening)
- Detailed mechanism of action data
- Confirmation of the current New Zealand supply and licensing situation
- A pulmonary toxicity monitoring plan
- A review of bleomycin's role in modern lymphoma regimens
- For glioma and primary pulmonary lymphoma: further research before any clinical consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.